58. Hypertrophic cardiomyopathy Clinical trials / Disease details
Clinical trials : 126 / Drugs : 135 - (DrugBank : 42) / Drug target genes : 46 - Drug target pathways : 162
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05556343 (ClinicalTrials.gov) | January 18, 2023 | 23/9/2022 | A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy | A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction | Cardiomyopathy, Hypertrophic | Drug: MYK-224 | Bristol-Myers Squibb | NULL | Recruiting | 18 Years | 70 Years | All | 36 | Phase 2 | United States;Italy;Poland;Spain |